Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | APP | P05067 | 13/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18832287 | 0.88 | ALDH1A1 (0.50) | ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1140820 | 0.86 | ALDH1A1 (0.48) | ALDH1A1APPCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL17075233 | 0.86 | ALDH1A1 (0.48) | ALDH1A1APPCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3823685 | 0.85 | ALDH1A1 (0.42) | ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1270753 | 0.85 | ALDH1A1 (0.42) | ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL316695 | 0.84 | ALDH1A1 (0.46) | ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL316600 | 0.84 | ALDH1A1 (0.46) | ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL92177 | 0.84 | ALDH1A1 (0.46) | ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5066935 | 0.83 | ALDH1A1 (0.55) | ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL18868387 | 0.82 | ALDH1A1 (0.44) | ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170283-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| CN-113754589-B | Compositions, methods, and systems for synthesizing and using contrast agents | 蓝瑟斯医学影像公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20240100199-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2024-03-28 | — | — | US | disclosed |
| US-11744906-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744906-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744906-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| CN-113754589-A | Compositions, methods, and systems for synthesis and use of contrast agents | 蓝瑟斯医学影像公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-107311935-B | Compositions, methods, and systems for synthesis and use of contrast agents | 蓝瑟斯医学影像公司 | 2021-10-08 | — | — | CN | disclosed |
| EP-3515912-B1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | CENTRE NAT RECH SCIENT (FR) | 2020-10-14 | — | — | EP | disclosed |
| US-20200230264-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2020-07-23 | — | — | US | disclosed |
| WO-2014026079-A2 | COMPOSITIONS, METHODS, AND SYSTEMS OF THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| US-20130228950-A1 | METHODS AND MATERIALS FOR FABRICATING MICROFLUIDIC DEVICES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130202729-A1 | Methods and Materials for Fabricating Laminate Nanomolds and Nanoparticles Therefrom | LIQUIDIA TECHNOLOGIES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-8444899-B2 | Methods and materials for fabricating microfluidic devices | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2013-05-21 | — | — | US | disclosed |
| US-8439666-B2 | Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom | LIQUIDIA TECHNOLOGIES, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120256354-A1 | METHODS AND MATERIALS FOR FABRICATING MICROFLUIDIC DEVICES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120189728-A1 | METHODS AND MATERIALS FOR FABRICATING LAMINATE NANOMOLDS AND NANOPARTICLES THEREFROM | LIQUIDIA TECHNOLOGIES, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8158728-B2 | Methods and materials for fabricating microfluidic devices | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-04-17 | — | — | US | disclosed |
| US-8128393-B2 | Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom | LIQUIDIA TECHNOLOGIES, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-7435495-B2 | Liquid materials for use in electrochemical cells | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170283-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | ALDH1A1 3040/4885APP 673/4885CHRNB2 1399/4885 |
| US-20200230264-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | ALDH1A1 3040/4885APP 673/4885CHRNB2 1399/4885 |
| US-20240100199-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | ALDH1A1 3040/4885APP 673/4885CHRNB2 1399/4885 |
| US-11744906-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | FABP3, TNNI3, TNNT2 | ALDH1A1 3040/4885APP 673/4885CHRNB2 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.